Month: August 2026

Drug Target Review explores why researchers at Racura Oncology are taking a fresh look at bisantrene, an anticancer drug first developed decades ago but later abandoned before reaching full clinical potential. The article highlights how modern molecular tools have revealed new mechanistic insights that were previously inaccessible, including evidence that bisantrene may suppress MYC, one of oncology’s most challenging targets, through interactions with G‑quadruplex DNA structures.

These findings have prompted renewed interest from biotech innovators who see value in revisiting discontinued compounds with strong biological rationale and known safety profiles. With new data emerging from preclinical studies and early clinical programmes, bisantrene is becoming a case study in how legacy molecules can be re‑evaluated and repurposed using today’s more advanced understanding of cancer biology.

Read the full story here.

MedNous recently sat down with the scientific and clinical leads at One‑carbon Therapeutics to explore how renewed attention on one‑carbon metabolism is reshaping the therapeutic landscape for hard‑to‑treat solid tumours. The feature traces the company’s journey from fundamental metabolic biology to a first‑in‑human programme, detailing how dysregulated folate flux, formate overflow and MTHFD1/2 activity create exploitable vulnerabilities in cancer cells — vulnerabilities that One‑carbon is now targeting with its first‑in‑class dual inhibitor, TH9619.

The article highlights how TH9619’s folate‑trapping mechanism selectively induces nucleotide shortage and DNA damage in tumour cells while sparing normal tissue, and how the ongoing ODIN Phase 1/2 study is designed to translate this biology into clinical impact for patients with advanced refractory cancers. With European sites actively enrolling and mechanistic data continuing to build, One‑carbon outlines why one‑carbon metabolism may represent one of the most promising new frontiers in precision oncology.

To read the full analysis of the science, strategy and clinical path ahead, access the complete MedNous article.